JP2012519207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519207A5 JP2012519207A5 JP2011552515A JP2011552515A JP2012519207A5 JP 2012519207 A5 JP2012519207 A5 JP 2012519207A5 JP 2011552515 A JP2011552515 A JP 2011552515A JP 2011552515 A JP2011552515 A JP 2011552515A JP 2012519207 A5 JP2012519207 A5 JP 2012519207A5
- Authority
- JP
- Japan
- Prior art keywords
- lenalidomide
- nitro
- solvent system
- piperidine
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN383/KOL/2009 | 2009-03-02 | ||
| IN383KO2009 | 2009-03-02 | ||
| IN463KO2009 | 2009-03-16 | ||
| IN463/KOL/2009 | 2009-03-16 | ||
| PCT/GB2010/050352 WO2010100476A2 (en) | 2009-03-02 | 2010-03-01 | Improved process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519207A JP2012519207A (ja) | 2012-08-23 |
| JP2012519207A5 true JP2012519207A5 (enExample) | 2013-04-18 |
| JP5727944B2 JP5727944B2 (ja) | 2015-06-03 |
Family
ID=54290149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552515A Expired - Fee Related JP5727944B2 (ja) | 2009-03-02 | 2010-03-01 | 改良プロセス |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8946265B2 (enExample) |
| EP (1) | EP2403845B1 (enExample) |
| JP (1) | JP5727944B2 (enExample) |
| CN (1) | CN102414196A (enExample) |
| AU (1) | AU2010220204B2 (enExample) |
| CA (1) | CA2753241C (enExample) |
| CY (1) | CY1115376T1 (enExample) |
| DK (1) | DK2403845T3 (enExample) |
| ES (1) | ES2487215T3 (enExample) |
| HR (1) | HRP20140686T1 (enExample) |
| NZ (1) | NZ595492A (enExample) |
| PL (1) | PL2403845T3 (enExample) |
| PT (1) | PT2403845E (enExample) |
| SI (1) | SI2403845T1 (enExample) |
| SM (1) | SMT201400100B (enExample) |
| WO (1) | WO2010100476A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法 |
| WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
| US8877932B2 (en) | 2010-03-08 | 2014-11-04 | Natco Pharma Limited | Anhydrous lenalidomide form-I |
| ES2705244T3 (es) | 2010-06-16 | 2019-03-22 | Inflammatory Response Res Inc | Levocetirizina y montelukast para el tratamiento de la gripe y del resfriado común |
| WO2013005229A1 (en) * | 2011-07-05 | 2013-01-10 | Hetero Research Foundation | Process for lenalidomide |
| CA2842316A1 (en) | 2011-07-19 | 2013-01-24 | Amplio Pharma, Llc | Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)piperidine-2,6-dione |
| CN102838586A (zh) * | 2012-09-20 | 2012-12-26 | 重庆泰濠制药有限公司 | 一种制备来那度胺的方法 |
| EP2968309A4 (en) | 2013-03-13 | 2016-08-31 | Inflammatory Response Res Inc | USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY |
| ES2660494T3 (es) | 2013-03-13 | 2018-03-22 | 14779507 | Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática |
| CN105228700A (zh) * | 2013-03-13 | 2016-01-06 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途 |
| WO2014160686A1 (en) * | 2013-03-26 | 2014-10-02 | Celgene Corporation | Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof |
| CN103601717A (zh) * | 2013-10-09 | 2014-02-26 | 湖南华腾制药有限公司 | 一种来那度胺的新型制备方法 |
| LV14985B (lv) | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
| US20170107193A1 (en) * | 2014-04-26 | 2017-04-20 | Shilpa Medicare Limited | Crystalline lenalidomide process |
| WO2016024286A2 (en) * | 2014-08-11 | 2016-02-18 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
| ES2733813T3 (es) * | 2014-08-19 | 2019-12-03 | Synthon Bv | Proceso para preparar una forma cristalina de lenalidomida |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| EP3393457A1 (en) | 2015-12-22 | 2018-10-31 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant |
| US10899793B2 (en) | 2016-05-27 | 2021-01-26 | Regents Of The University Of Minnesota | Melanocortin ligands and methods of use thereof |
| US11124541B2 (en) | 2016-10-18 | 2021-09-21 | Regents Of The University Of Minnesota | Chimeric melanocortin ligands and methods of use thereof |
| EP3687987A4 (en) * | 2017-09-27 | 2021-03-24 | Biocon Limited | CRYSTALLINE FORMS OF LENALIDOMIDE |
| WO2019138424A1 (en) * | 2018-01-11 | 2019-07-18 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
| US11332499B2 (en) | 2018-08-16 | 2022-05-17 | Regents Of The University Of Minnesota | Cyclic peptides and methods of use thereof |
| CN111196800B (zh) * | 2018-11-19 | 2022-10-11 | 欣凯医药化工中间体（上海）有限公司 | 一种制备来那度胺的方法 |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| WO2022144924A1 (en) * | 2021-01-04 | 2022-07-07 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| NZ554068A (en) | 2004-09-03 | 2009-07-31 | Celgene Corp | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines |
| EP2136896B1 (en) | 2007-04-16 | 2015-01-21 | Momenta Pharmaceuticals, Inc. | Multi-dimensional chromatographic methods for separating n-glycans |
| JP2011506950A (ja) | 2007-12-14 | 2011-03-03 | ジェネリクス・（ユーケー）・リミテッド | クロピドグレルを分析するためのｈｐｌｃ法 |
| KR20100124710A (ko) | 2008-03-11 | 2010-11-29 | 닥터 레디스 레보러터리즈 리미티드 | 레날리도미드의 제조 |
| CA2741927A1 (en) | 2008-11-03 | 2010-06-03 | Generics [Uk] Limited | A crystalline form of lenalidomide and a process for its preparation |
| WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
-
2010
- 2010-03-01 WO PCT/GB2010/050352 patent/WO2010100476A2/en not_active Ceased
- 2010-03-01 US US13/254,249 patent/US8946265B2/en active Active
- 2010-03-01 JP JP2011552515A patent/JP5727944B2/ja not_active Expired - Fee Related
- 2010-03-01 CA CA2753241A patent/CA2753241C/en active Active
- 2010-03-01 NZ NZ595492A patent/NZ595492A/xx not_active IP Right Cessation
- 2010-03-01 HR HRP20140686AT patent/HRP20140686T1/hr unknown
- 2010-03-01 SI SI201030679T patent/SI2403845T1/sl unknown
- 2010-03-01 DK DK10707950.1T patent/DK2403845T3/da active
- 2010-03-01 ES ES10707950.1T patent/ES2487215T3/es active Active
- 2010-03-01 AU AU2010220204A patent/AU2010220204B2/en not_active Ceased
- 2010-03-01 PT PT107079501T patent/PT2403845E/pt unknown
- 2010-03-01 PL PL10707950T patent/PL2403845T3/pl unknown
- 2010-03-01 CN CN2010800195527A patent/CN102414196A/zh active Pending
- 2010-03-01 EP EP10707950.1A patent/EP2403845B1/en active Active
-
2014
- 2014-07-24 CY CY20141100562T patent/CY1115376T1/el unknown
- 2014-07-28 SM SM201400100T patent/SMT201400100B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101253163B (zh) | 4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮化合物的制备方法 | |
| JP5426693B2 (ja) | アゴメラチンハロゲン化水素複合体及びその製造方法 | |
| EP2305667A2 (en) | Nilotinib intermediates and preparation thereof | |
| US20120071509A1 (en) | process | |
| JP2016512824A5 (enExample) | ||
| US20110028508A1 (en) | Novel process for the preparation of scopine esters | |
| JP2009542785A5 (enExample) | ||
| JP5373996B2 (ja) | サクサグリプチン中間体、サクサグリプチン多形及びそれらの調製方法 | |
| WO2015163447A1 (ja) | ４環性化合物の新規結晶 | |
| CN102869650B (zh) | 一种厄洛替尼碱的新晶型及其制备方法 | |
| CN110891947B (zh) | 制备艾乐替尼或其药学上可接受的盐的方法 | |
| US10392364B2 (en) | Process for synthesis of lenalidomide | |
| CN111315722B (zh) | 制备月桂酰阿立哌唑的方法 | |
| US9850267B2 (en) | Crystalline fosaprepitant dicyclohexylamine salt and its preparation | |
| JP2022060192A5 (enExample) | ||
| CN103497175A (zh) | 制备来那度胺的方法 | |
| KR101032600B1 (ko) | 고순도 레바미피드의 제조방법 | |
| WO2020053795A2 (en) | Process for the preparation of acalabrutinib and its intermediates | |
| CN103298795A (zh) | 用于制备来曲唑的纯中间体 | |
| WO2014188445A1 (en) | PROCESS FOR THE PREPARATION OF (3β)-17-(3-PYRIDINYL)ANDROSTA-5,16-DIEN-3-YL ACETATE AND POLYMORPH THEREOF | |
| CN111808172B (zh) | 肺念菌素b0衍生物及其制备方法和用途 | |
| EP3679030B1 (en) | A process for preparation of triaminopyrimidine compound and intermediates thereof | |
| CN101029045A (zh) | 一种制备4－(3－吡啶基)－1h－咪唑－1－丁胺的方法 | |
| CN106279112A (zh) | 一种克里唑替尼中间体及其制备方法和应用 | |
| WO2018021517A1 (ja) | ４－アルコキシ－３－トリフルオロメチルベンジルアルコールの製造方法 |